Palmoplantar Keratoderma and Congenital Alopecia Type 2 (PPK-CA2)

Palmoplantar keratoderma and congenital alopecia type 2 (PPK-CA2) is a very rare, inherited skin and hair condition. Babies are born with little or no scalp hair (alopecia) that usually does not grow in later. Over time, the skin on the palms and soles becomes abnormally thick (keratoderma). Many people also develop tight, tapered fingers, hand contractures, and bands of skin that can constrict digits (pseudo-ainhum). Eye lens clouding (cataracts) can appear in childhood or adolescence. PPK-CA2 is passed in an autosomal recessive pattern. Recent studies show that harmful (biallelic) variants in the LSS gene—an enzyme in the cholesterol-making pathway—can cause this syndrome. This link explains why the skin’s outer layer (stratum corneum) and hair shafts do not form normally. ScienceDirect+3National Organization for Rare Disorders+3Mouse Genome Informatics+3

PPKCA2 is a very rare genetic skin condition present from birth. The two main signs are (1) congenital alopecia—scalp and body hair are absent or very sparse—and (2) thick, hard skin on the palms and soles (palmoplantar keratoderma, PPK). Over time, the thick skin may tighten the fingers and toes, causing sclerodactyly, painful bands that can constrict a digit (pseudoainhum), and sometimes contractures that limit movement. Childhood-onset cataracts have been described in many patients. The condition follows an autosomal recessive inheritance pattern (both copies of the gene must be altered). Orpha+2MalaCards+2

Recent genetic studies identify biallelic pathogenic variants in the LSS gene (lanosterol synthase) as a cause of PPKCA2. LSS is a key enzyme in the cholesterol biosynthesis pathway; loss-of-function variants reduce lanosterol production and disrupt skin barrier cornification, which likely drives the severe PPK. These reports also document associated features such as early cataracts and pseudoainhum. PubMed+1

Other names

This condition appears under several names in medical references. Knowing them helps when searching for information:

• Autosomal recessive palmoplantar keratoderma and congenital alopecia (PPK-CA).

• Cataract–Alopecia–Sclerodactyly syndrome (CAS).

• Palmoplantar keratoderma and congenital alopecia, Wallis type.

• Palmoplantar hyperkeratosis and congenital alopecia.
  All of these refer to the same recessive form (Type 2). Genetic and Rare Diseases Center+1

Doctors describe two recognizable forms:

• Type 1 (PPK-CA1) is autosomal dominant. It causes severe thickening of palms/soles and alopecia but typically lacks the severe finger tapering and constriction seen in Type 2. Nail changes may occur.

• Type 2 (PPK-CA2) is autosomal recessive. It includes congenital alopecia plus progressive palm-sole thickening that can lead to sclerodactyly, contractures, tapering digits, and pseudo-ainhum. Cataracts are common.
  These patterns help with counseling and genetic testing. NCBI+1

---

Types

Because “type” here refers mainly to inheritance and clinical pattern, a practical, patient-friendly breakdown is:

1. PPK-CA1 (Autosomal Dominant) – Born with little or no hair, later marked thickening of palms/soles; some may have nail dystrophy. Family history often positive in each generation. NCBI

2. PPK-CA2 (Autosomal Recessive) – Born with alopecia; progressive palmoplantar thickening leading to sclerodactyly, contractures, tapered digits, and possible bands that constrict fingers or toes; cataracts often appear early. Parents are usually healthy carriers. National Organization for Rare Disorders+1

---

Causes

Important note: In this rare disease, the primary, proven cause is biallelic pathogenic variants in the LSS gene (lanosterol synthase), which disrupts cholesterol synthesis crucial for normal skin and hair formation. The other items below describe mechanisms that flow from this cause or factors that can worsen or unmask symptoms; they are not independent “root causes.” PubMed+1

1. LSS gene variants (biallelic). Harmful changes in both copies of LSS reduce lanosterol synthase activity, disturbing the cholesterol pathway and leading to defective skin cornification and hair growth. PubMed

2. Autosomal recessive inheritance. A child inherits one nonworking LSS copy from each carrier parent; the child is affected, while parents are unaffected carriers. National Organization for Rare Disorders

3. Disturbed cholesterol synthesis in skin. The outer skin barrier needs cholesterol; when it is low or imbalanced, the stratum corneum thickens abnormally, causing keratoderma. PubMed

4. Defective hair follicle structure. Cholesterol derivatives guide hair shaft formation; disruption leads to congenital alopecia or very sparse hair. PubMed

5. Abnormal keratinocyte maturation. When lipid processing falters, skin cells do not shed normally and instead pile up into thick callus-like plates. PMC

6. Secondary skin inflammation. Cracks and thick scales allow irritation and infection, promoting redness and pain that can accelerate thickening. Medscape+1

7. Mechanical pressure and friction. Daily stress on palms/soles aggravates hyperkeratosis and fissuring in people with the genetic defect. Medscape

8. Dry environment or low humidity. Dryness increases scaling and splitting, worsening symptoms. VisualDx

9. Heat and sweating. Excess sweat trapped under thick skin can macerate and inflame tissue, making PPK more uncomfortable. Medscape

10. Minor infections. Bacterial or fungal overgrowth in fissures worsens pain and thickening until treated. VisualDx

11. Tight footwear. Pressure points speed callus formation on soles in keratoderma. Medscape

12. Nutritional stress on skin barrier. While not causal, poor hydration and low essential skin lipids can aggravate cracking and scaling. VisualDx

13. Repeated manual labor. Heavy hand use deepens fissures and can precipitate painful splits. Medscape

14. Delayed wound healing in thick skin. Thickened plates heal slowly, which prolongs inflammation and discomfort. VisualDx

15. Pseudo-ainhum bands. Tight keratotic bands arising from abnormal cornification can constrict digits and endanger circulation. National Organization for Rare Disorders

16. Sclerodactyly (tight fingers). Persistent thickening and scarring around fingers reduce flexibility, contributing to contractures. National Organization for Rare Disorders

17. Childhood cataracts in Type 2. Lens clouding is part of the phenotype in the recessive form, likely linked to shared lipid pathway effects in the eye. National Organization for Rare Disorders

18. Nail involvement (some cases). Thickened or dystrophic nails may reflect the same cornification problem affecting nail plates. NCBI

19. Genetic modifiers (theoretical). Other genes in the lipid/keratin pathways might influence severity from family to family. Evidence is emerging. PubMed

20. Environmental skin irritants. Harsh soaps, solvents, or cold exposure can worsen dryness and cracking. VisualDx

---

Symptoms and Signs

1. Congenital alopecia. Babies are born with very sparse or absent scalp hair, and hair usually does not grow in later childhood. Body hair may also be reduced. National Organization for Rare Disorders

2. Palmoplantar keratoderma (PPK). The skin of the palms and soles thickens into yellowish, plate-like areas that may crack and hurt with walking or gripping. Medscape+1

3. Painful fissures. Deep splits can form in thick skin, especially on heels and finger creases, causing stinging or bleeding. VisualDx

4. Sclerodactyly. Fingers become tight and tapered due to persistent thickening and scarring around the digits. National Organization for Rare Disorders

5. Contractures. Joints of fingers may become fixed in a bent position over time, limiting function. National Organization for Rare Disorders

6. Pseudo-ainhum. Constricting keratotic bands can partially or fully encircle fingers or toes, threatening circulation and sometimes requiring urgent care. National Organization for Rare Disorders

7. Cataracts (often early). Lens clouding may appear in childhood or teen years in Type 2 and can blur vision or cause glare. National Organization for Rare Disorders

8. Nail changes (variable). Some people have thick, rough, or misshapen nails; others have nearly normal nails. NCBI

9. Hyperhidrosis or maceration. Sweat trapped under thick skin can soften and irritate skin, causing discomfort. Medscape

10. Recurrent skin infections. Bacteria or fungi can grow in fissures, causing redness, swelling, or discharge that needs treatment. VisualDx

11. Tender calluses with pressure. Standing, walking long distances, or manual work increases pain over thickened areas. Medscape

12. Itching or burning. Irritated thick skin may itch or burn, especially in dry weather. VisualDx

13. Functional limits. Gripping tools or prolonged walking may be hard because of pain and stiffness. Medscape

14. Psychosocial stress. Visible alopecia and hand/foot changes can affect confidence and participation at school or work. General PPK guidance highlights quality-of-life impact. Medscape

15. Eye symptoms from cataracts. Glare, halos, or blurred vision can appear as cataracts progress, signaling a need for eye evaluation. National Organization for Rare Disorders

---

Diagnostic Tests

Physical examination

1. Full skin exam of palms and soles. A clinician looks for diffuse, yellow-thickened skin, sharp borders, fissures, and any constricting bands around digits. Patterns help distinguish Type 1 vs Type 2. Medscape

2. Hair and scalp assessment. The examiner documents congenital absence or sparseness of hair, hair shaft texture, and eyebrow/eyelash involvement. National Organization for Rare Disorders

3. Nail inspection. Nails are checked for thickening, ridging, or dystrophy, which can occur in some patients. NCBI

4. Joint and hand function check. Range of motion, signs of contractures, and finger tapering (sclerodactyly) are noted and followed over time. National Organization for Rare Disorders

5. Foot posture and gait review. Callus distribution, heel cracks, and areas of pressure pain guide supportive care planning. Medscape

Manual/bedside tests

6. Hair-pull and trichoscopy. Gentle pull testing and dermatoscope viewing help assess hair shaft fragility and density in congenital alopecia. National Organization for Rare Disorders

7. Goniometry of finger joints. Measuring angles quantifies contractures and tracks change with therapy. National Organization for Rare Disorders

8. Grip strength testing. Hand dynamometry documents functional impact from pain, thick skin, or joint stiffness. Medscape

9. Skin hydration/TEWL assessment (clinic devices). Simple noninvasive tools estimate dryness and barrier function to guide emollient regimens. VisualDx

10. Band assessment for pseudo-ainhum. A clinician gently probes any constricting ring to judge depth and circulation risk, deciding if urgent release is needed. National Organization for Rare Disorders

Laboratory & pathological tests

11. Genetic testing for LSS. Sequencing looks for pathogenic variants in both gene copies; finding them confirms the diagnosis and clarifies inheritance risk for the family. PubMed

12. Targeted PPK gene panels. Broader panels check other PPK-related genes when the presentation is atypical, ensuring similar disorders are not missed. Medscape

13. Skin biopsy (histology). Under a microscope, thickened stratum corneum and altered cornification patterns support a keratoderma diagnosis and rule out other causes. PMC

14. Fungal culture/KOH from fissures. Testing detects secondary infections that worsen pain and must be treated to allow skin healing. VisualDx

15. Basic labs if infection suspected. A clinician may order CBC/CRP when there is redness, swelling, or drainage to guide antibiotics. (General PPK care practice.) Medscape

16. Family carrier testing. Once the proband’s LSS variants are known, parents and siblings can be tested for counseling and future planning. National Organization for Rare Disorders

Electrodiagnostic tests

17. Nerve conduction studies (selected cases). Not routine for PPK-CA2, but considered if numbness or nerve entrapment is suspected due to severe skin thickening or constricting bands. Medscape

18. EMG (selected cases). Rarely used; may be considered if hand weakness is disproportionate to skin findings, to look for another cause. Medscape

Imaging & specialized ocular tests

19. Hand/foot X-rays. Imaging documents advanced constriction, bone changes, or joint deformities when pseudo-ainhum or severe contracture is present. National Organization for Rare Disorders

20. Slit-lamp eye exam. An ophthalmologist examines the lenses to detect early cataracts common in the recessive type. Regular follow-up is advised. National Organization for Rare Disorders

Non-pharmacological treatments (therapies & other care)

Practical note: Because PPKCA2 is ultra-rare, most interventions are extrapolated from broader inherited PPK care. Evidence strength varies (case reports/series > expert reviews > extrapolation). Where available, I cite disease-specific or PPK-inherited evidence.

1. Intensive emollient regimen (multiple daily applications).
   Thick, occlusive moisturizers soften hard skin, reduce fissuring, and improve comfort and hand/foot function. Apply after bathing and before sleep; cotton gloves/socks can enhance penetration overnight. PMC

2. Regular keratolytic debridement (home + clinic).
   Careful mechanical paring (podiatry/dermatology) plus home pumice filing reduces bulk hyperkeratosis, decreases callus pain, and may limit pseudoainhum progression by lowering circumferential pressure. PMC

3. Topical keratolytics (non-drug care step).
   Although “topical keratolytics” include drug actives (below), their technique matters: short contact under occlusion, step-up schedules, and rotating agents prevent irritation and tachyphylaxis. PMC

4. Moist heat soaks before care.
   Warm water or urea-infused soaks soften plaques, making paring safer and improving comfort. PMC

5. Protective padding and pressure off-loading.
   Silicone sleeves, gel toe caps, metatarsal pads, and custom orthoses reduce focal pressure and shear on soles, lowering fissure risk and pseudoainhum tension. PMC

6. Footwear optimization.
   Wide toe boxes, rocker-bottom soles, and cushioned insoles reduce plantar load and pain; breathable socks limit maceration. PMC

7. Hand ergonomics & task modification.
   Grip aids, cushioned handles, and avoiding repetitive friction help minimize fissures and pain. PMC

8. Wound care for fissures.
   Moist wound healing with petrolatum-based ointment and non-adherent dressings prevents infection and speeds closure of painful cracks. PMC

9. Physiotherapy for range of motion.
   Gentle stretching helps counteract sclerodactyly and maintain dexterity; splinting may preserve finger extension. Orpha

10. Pseudoainhum monitoring plan.
    Routine inspection for constriction bands; early referral prevents ischemia and tissue loss. Orpha

11. Cataract surveillance (ophthalmology).
    Early eye exams detect lens opacity; timely surgery can restore vision if cataracts progress. Orpha

12. Genetic counseling (autosomal recessive).
    Discuss recurrence risk (25% with two carrier parents), testing options, and implications for siblings. Orpha

13. Targeted topical simvastatin–cholesterol (compounded) under specialist care.
    Where available and appropriate, supervised use may reduce PPK thickness by supporting cholesterol-pathway function. OUP Academic

14. Education on triggers and skin care routines.
    Heat, friction, and low humidity worsen PPK; scheduled care prevents painful flares. PMC

15. Psychosocial support.
    Visible alopecia and hand/foot disability can affect schooling, work, and self-image; early psychosocial support improves quality of life. PMC

16. School/workplace accommodations.
    Keyboard rests, breaks for hand soaks/emollients, and footwear allowances reduce morbidity. PMC

17. Infection prevention habits.
    Prompt care for fissures and maceration lowers cellulitis risk; teach early warning signs (redness, warmth, drainage). PMC

18. Sun and irritant avoidance on compromised skin.
    Fragrance-free cleansers and gloves for detergents reduce dermatitis that can aggravate PPK. PMC

19. Nail care if dystrophy present.
    Regular trimming and cushioning reduce trauma at nail folds. MalaCards

20. Multidisciplinary care pathway.
    Dermatology, podiatry/hand surgery, ophthalmology, genetics, physiotherapy, and mental health should coordinate care plans. PMC

---

Drug treatments

There is no FDA-approved drug specifically for PPKCA2. The following are symptomatic or pathway-informed (off-label) options used in inherited PPKs and, when possible, anchored to FDA labeling for the active ingredient. Use under specialist supervision; contraception and lab monitoring are critical for systemic retinoids.

1) Oral acitretin (retinoid; cornerstone for inherited PPK).
Class & purpose: Systemic retinoid that normalizes epidermal differentiation, reduces scale and thickness, and can reverse pseudoainhum in some keratoderma syndromes. Dose/time: Commonly 10–25 mg daily (specialist adjusts to response); months of therapy often needed; taper or pulse strategies used to balance efficacy and side effects. Mechanism: Nuclear RAR/RXR agonism modulates keratinocyte proliferation/differentiation. Key adverse effects: Teratogenicity (strict contraception), dry lips/skin, hair loss, elevated lipids, liver enzyme changes. Evidence: Case reports and reviews highlight benefit in PPK and pseudoainhum. Label source: SORIATANE® (acitretin). FDA Access Data+2PubMed+2

2) Oral isotretinoin (alternative systemic retinoid).
Use: Consider if acitretin is unsuitable; similar keratinocyte effects. Cautions: Highly teratogenic; laboratory and pregnancy program requirements apply. Label source: ACCUTANE®/ABSORICA® isotretinoin. FDA Access Data+1

3) Topical tazarotene (0.05–0.1% gel/cream).
Purpose: Plaque thinning in focal PPK; often combined with keratolytics and emollients. Mechanism: Topical retinoid normalizing differentiation. Adverse effects: Irritation; avoid in pregnancy. Label source: TAZORAC®/ARAZLO™. FDA Access Data+2FDA Access Data+2

4) Topical urea (20–40%).
Purpose: Strong keratolytic emollient to soften plaques and fissures; improves penetration of other topicals. Adverse effects: Stinging on fissures. Label source: DailyMed/FDA SPL. DailyMed+1

5) Topical salicylic acid (6–20%).
Purpose: Keratolytic to reduce scale bulk; often used in combination with urea. Safety note: Avoid excessive coverage (systemic salicylate risk), especially under occlusion or in children. Label source: FDA SPL/DailyMed. FDA Access Data+2FDA Access Data+2

6) Compounded topical simvastatin 2% + cholesterol 2%.
Purpose: Pathway-informed therapy for LSS-related disease; small case experience shows improvement in PPK thickness and finger mobility. Mechanism: Statin may rebalance cholesterol pathway flux with added cholesterol supporting barrier lipids. Status: Off-label; compounded. Clinical report: BJD 2025. OUP Academic

7) High-potency topical corticosteroids (e.g., clobetasol under short occlusion on fissured, inflamed areas).
Purpose: Reduce secondary inflammation/itch; short courses only to minimize atrophy. (FDA labels available for specific products; use judiciously). PMC

8) Topical calcipotriene (vitamin D analog).
Purpose: Sometimes layered with keratolytics for hyperkeratotic plaques; data in inherited PPK are limited but mechanistically plausible. (FDA label exists for psoriasis; off-label here). PMC

9) Oral analgesics (acetaminophen/NSAIDs as appropriate).
Purpose: Pain from fissures and contractures; use cautiously with comorbidities. (FDA labels standard). PMC

10) Short-course oral antibiotics for secondary bacterial infection.
Purpose: Treat cellulitis or infected fissures; culture-guided when possible. (FDA labels vary by agent). PMC

11) Topical antibiotics (e.g., mupirocin for localized infection).
Purpose: Limited, short-term use on superinfected fissures. (FDA label exists; off-label for this indication). PMC

12) Antifungals when maceration/superinfection present (topical azoles).
Purpose: Control interdigital maceration that worsens pain and fissuring. (FDA labels for agents). PMC

13) Keratolytic combinations (urea + salicylic acid).
Purpose: Synergistic thinning with emollience. Clinical context: Frequently used in inherited PPK and ichthyoses. Lippincott

14) Petrolatum-based ointments for fissures (wound care).
Purpose: Promote moist healing and barrier restoration. PMC

15) Barrier repair creams (ceramide-dominant).
Purpose: Support stratum corneum lipids; adjunctive to keratolytics. PMC

16) Off-label intermittent isotretinoin “pulses” (women of childbearing potential) under strict risk management.
Purpose: Attempt to balance benefit and teratogenic risk; described in pseudoainhum-threatened settings. Context review: Pseudoainhum management literature. PMC

17) Topical retinoid rotations (tazarotene with rest days).
Purpose: Maintain effect while limiting irritation. Context: Inherited PPK reviews. PubMed

18) Off-label EGFR inhibitor case report (erlotinib) in inherited PPK (not PPKCA2 specific).
Purpose: Experimental; not standard. Context: Review mentions transient benefit. PMC

19) Peri-operative antibiotics (if surgery for pseudoainhum).
Purpose: Reduce infection risk around band release/grafting. PMC

20) Peri-operative analgesia and topical steroid “cool-down” post-debridement.
Purpose: Pain and inflammation control to improve rehab and wound healing. PMC

---

Dietary molecular supplements

No supplement cures PPKCA2. Use as adjuncts to skin care and nutrition; avoid “mega-doses.” Evidence summarized below is indirect or supportive for skin barrier/hair biology—not disease-specific—unless stated.

1. Essential fatty acids (omega-3 from fish oil).
   May modestly support skin barrier lipids and inflammation balance; consider standard doses (e.g., 1–2 g/day EPA+DHA if no contraindications). Evidence for inherited PPK is extrapolative. PMC

2. Vitamin D (correct deficiency).
   Supports epidermal differentiation; supplement only if low per labs (typical 800–2000 IU/day, individualized). PMC

3. Zinc (correct deficiency).
   Essential for keratinocyte function and wound healing; supplement if low; avoid excess. PMC

4. Biotin (only if deficiency).
   Helps some brittle nail/hair disorders when deficient; routine high-dose use without deficiency is not supported. PMC

5. Niacinamide (B3).
   Topical/oral B3 may aid barrier function and decrease TEWL; limited direct evidence in inherited PPK. PMC

6. Ceramide-containing topicals (lipid “supplement” to skin).
   Restores barrier lipids; use liberally with keratolytics. PMC

7. Protein-adequate diet.
   Adequate protein supports wound healing and nail/hair growth; not a cure but important. PMC

8. Lanosterol eye drops—not recommended** outside trials.**
   Despite in-vitro/animal excitement, human evidence does not support clinical cataract reversal; care should follow standard ophthalmology. Nature+1

9. General multivitamin if dietary insufficiency exists.
   Covers gaps without excess; avoid high vitamin A with retinoid therapy. PMC

10. Probiotics (consider only for general skin health; evidence weak).
    No specific benefit proven for PPKCA2; safe if desired. PMC

---

Immunity-booster / regenerative / stem-cell” drugs

There are no approved immune-booster or stem-cell drugs for PPKCA2. Below are realistic clarifications frequently requested online:

1. Topical simvastatin–cholesterol (pathway-targeted, not immune-booster).
   Mechanism supports lipid pathway, not immunity; early case data only. OUP Academic

2. Systemic retinoids (acitretin, isotretinoin).
   These are not immune boosters; they regulate keratinocyte differentiation and reduce hyperkeratosis. FDA Access Data+1

3. Biologics (e.g., anti-TNF/IL-inhibitors).
   No evidence in PPKCA2; not recommended outside trials. PMC

4. Stem-cell therapies.
   No clinical evidence for cutaneous regeneration in PPKCA2; avoid unregulated clinics. PMC

5. Lanosterol or oxysterols systemically.
   Not supported in humans for cataracts; avoid outside trials. Nature

6. Topical growth factors.
   Insufficient evidence in inherited PPK; prioritize standard keratoderma care. PMC

---

Surgeries (what is done and why)

1. Release of constricting bands (pseudoainhum) with Z-plasty.
   Purpose: restore circulation and prevent auto-amputation; often combined with debulking of surrounding hyperkeratosis. PMC

2. Skin grafting after band release (full-thickness where needed).
   Purpose: resurface and prevent re-constriction; meticulous post-op care required. PMC

3. Debulking/dermabrasion of focal hyperkeratosis.
   Purpose: reduce pain and allow better function/glove/shoe wear; adjunct to medical care. PMC

4. Contracture release procedures (hand surgery).
   Purpose: improve mobility when sclerodactyly limits function despite therapy. Orpha

5. Cataract extraction (standard phacoemulsification with IOL).
   Purpose: restore vision in early-onset cataracts when clinically significant. Orpha

---

Preventions

1. Daily emollients and scheduled keratolytics to prevent fissures. PMC

2. Pressure off-loading (pads, orthoses) and friction avoidance. PMC

3. Breathable footwear/socks; moisture control to prevent maceration. PMC

4. Protective gloves for wet work/chemicals; fragrance-free cleansers. PMC

5. Early wound care for cracks to prevent infection. PMC

6. Routine checks for finger/toe bands; fast referral if color/temperature changes. PMC

7. Ophthalmology follow-up schedule for cataracts. Orpha

8. Genetic counseling before family planning (autosomal recessive risk). Orpha

9. Avoid excessive heat/occlusion that worsens hyperkeratosis. PMC

10. Keep nails short and edges smooth to reduce tearing of adjacent skin. MalaCards

---

When to see a doctor (or go urgently)

• Urgent, same-day: A finger or toe suddenly becomes cold, blue, very painful, or numb—possible pseudoainhum ischemia. Immediate surgical assessment reduces risk of tissue loss. PMC

• Soon (days): New or spreading redness, warmth, swelling, pus from a fissure (possible cellulitis). PMC

• Routine (weeks): Worsening hand/foot function, increasing contractures, or vision blur/glare suggesting cataract progression. Orpha

---

What to eat & what to avoid (simple guidance)

• Emphasize: Balanced diet with adequate protein, fruits/vegetables, and omega-3-rich fish; hydrate well—dry skin worsens with dehydration. Correct documented deficiencies (vitamin D, zinc) with clinician guidance. PMC

• Limit/Avoid: Very high vitamin A intake if on retinoids; excessive alcohol if on acitretin (hepatotoxicity risk), and unproven “cure” supplements marketed online. FDA Access Data

---

FAQs

1) Is PPKCA2 the same as other keratodermas?
No. Many genetic PPKs exist. PPKCA2 combines severe palm/sole thickening with congenital alopecia and often cataracts; it’s autosomal recessive and linked to LSS. PubMed

2) Can creams cure it?
No cure yet. Daily emollients + keratolytics and retinoids can reduce thickness and pain. A small report suggests topical simvastatin–cholesterol may help. PubMed+1

3) Will my child lose fingers or toes?
Not if pseudoainhum is spotted early and treated. Watch for tight bands, color change, or pain and seek urgent care. Retinoids and surgery can help. PMC

4) Why cataracts?
LSS defects affect cholesterol/lanosterol biology in tissues including the lens, predisposing to cataracts in some patients. PubMed

5) Are lanosterol eye drops proven?
No. Human studies do not support cataract reversal with lanosterol; surgery remains standard. Nature

6) Is it contagious?
No. It’s inherited. Orpha

7) Can adults be diagnosed?
Yes. Genetic testing can confirm LSS variants in suspected cases at any age. PubMed

8) Do retinoids thin the skin too much?
They normalize thickened skin. Side effects (dryness, lab changes) are monitored; teratogenicity requires strict contraception. FDA Access Data

9) Should we try biologics?
No evidence for PPKCA2; not recommended outside research. PMC

10) Is hair loss permanent?
Alopecia is congenital and typically persistent; cosmetic options (wigs, scalp care) help with comfort and confidence. Orpha

11) Can diet fix it?
Diet supports overall skin health but cannot cure PPKCA2. Correct deficiencies; avoid high vitamin A with retinoids. PMC+1

12) What’s the outlook?
With consistent care, many complications are preventable. Early pseudoainhum management and cataract care are key. Orpha

13) Are there clinical trials?
Check registries; as of now, evidence includes case reports/series and targeted topical statin-cholesterol experience. OUP Academic

14) Will it affect school/work?
Yes, sometimes. Ergonomic aids, footwear modifications, and care routines help maintain function. PMC

15) Can relatives be carriers?
Yes. Siblings may be carriers; genetic counseling explains testing and recurrence risks. Orpha

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 12, 2025.